

(LXGTF)'s Cardiovascular Diagnostic Medical Device Could Disrupt An Industry Worth Billions

By **Abraham Mason** - Oct 1, 2017

NEWS | Lexington Biosciences (LXGTF) Receives HeartSentry Trial Units

This growth will be driven by increased use of biotech in government, financial, and healthcare sectors. While companies typically try to appeal to different markets, there have been major innovations in the healthcare industry for wearable medical devices.

Big name companies like Apple, Alphabet the parent company of Google, and International Business Machines Corp. are making their way into the healthcare sector as well. With their expertise and ample resources it can change the industry completely in a good way.

The potential for growth in this market right now is remarkable. **The wearable medical device market is projected to reach \$12.14 billion by 2021** from \$5.31 billion in 2016, with a CAGR of 18.0% according to MarketsandMarkets research. The growth is driven by increased health awareness, technological advancements in medical devices, and increased smartphone health apps that are compatible with these wearable devices.



A study by ITOnline shows that two-thirds of Americans already favor digital health management rather than physical. The study also shown that 79 percent of Americans stated

they would utilize a wearable device to manage their health. About 45% wanted to track symptoms while 43% percent wanted it to manage a specific health condition.

The healthcare model is evolving and wearables correlate significantly to this new model. Care is no longer visiting a doctor or medical center. Care is coming to you the patient, wherever you are with your smartphone.

WHAT'S BETTER THAN THAT?

Lexington Biosciences (LXGTF) is a developmental stage medical device company that is developing a new non-invasive diagnostic device that can measure and monitor cardiovascular health via their **Cardiovascular Diagnostic Medical Device, HeartSentry**.

Before, this development the only way to measure this was using ultrasound and other complex technologies. Currently, the company is in the final stages of releasing the developed product for clinical studies.

According to the **World Health Organization (WHO)** cardiovascular disease and stroke are the primary cause of death worldwide. In the United States alone, approximately 1.5 million people annually suffer from heart attacks and more than 250,000 people die within the first hour of an attack. Sadly, as many as 50% of people do not show signs or symptoms until it is too late.

Lexington Biosciences (LXGTF) is revolutionizing not only the healthcare market but the Biometric market with a product first in class to monitor vascular health and detect cardiovascular disease even at a premature stage, the Cardiovascular Diagnostic Medical Device, HealthSentry. With simple and effective technology, this product can save a life.

The **(LXGTF)'s** product, **HEARTSENTRY**, quantifies the function of the endothelium or the cells that line the arteries. You can envision endothelium as a defense against plaque from developing inside the artery wall.

The cells also create elements that prevent blood clots from developing in the vessel. These cells are vital to the prevention of atherosclerosis, the hardening and narrowing of the arteries and the usual culprit for heart attacks and stroke.

With the familiar design to that of a blood pressure machine, this life saving technology has an ease of use while adding modern day technology. **HEARTSENTRY** utilizes Bluetooth and Cloud technology to provide accurate reporting of an individual's cardiovascular health to directly target the unmet medical need for early detection.

The Lawrence Berkeley National Laboratory (Berkeley Lab) is synonymous with "excellence." Thirteen Nobel Prizes are associated with Berkeley Lab.

This ground-breaking Cardiovascular Diagnostic Medical Device technology was invented and developed over a fifteen-year period by Thomas F. Budinger, M.D. Ph.D, and Jonathan S. Maltz, Ph.D, joint-winners of an international award in 2006 for their instrument to assess endothelial function.

The goal is for (**LXGTF**)'s HeartSentry to become the standard of care for first line evaluation of a person's cardiovascular health for cardiologists, general practitioners, and ultimately patients.

Top Leaders Are On Board

It's not just the technology that's beginning to draw attention to (**LXGTF**). It's also the top brass in the industry making a move to join the efforts:

Eric Willis, Chief Executive Officer

Mr. Willis is an entrepreneurial healthcare technology executive with a track record of success in bringing products from initial concept to market. He is the past President and Chief Operating Officer of ParaPatch (2013–2015), where he was responsible for the development and launch of an over-the-counter women's health product for the treatment of urinary incontinence. Prior to this, he served as President and CEO of InSite Medical Technologies (2008–2013) a venture backed start-up medical device company that developed a new method for performing epidural anesthesia. From 1994–2008 he served in a variety of executive and operational roles for cardiovascular medical device companies.

Rocco Rossi, Director

A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. His unique blend of experience intersects general management, philanthropy, public policy, politics, business strategy, and new media. As CEO of the Heart and Stroke Foundation – one of Canada's largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over \$500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP.

Doug Janzen, Chairman

Mr. Janzen has 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Mr. Janzen is currently Co-Founder and Managing Director of Northview Ventures. He serves as Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, he was President and CEO of Cardiome Pharma (NASDAQ: CRME) During this time he raised over \$300 million from investors, completed over \$1 billion in licensing deals, and led a partnership with Merck to bring Cardiome's lead product, Brinavess, through to clinical approval and marketing in Europe.

Greg Robertson, M.D., Medical Advisor

Dr. Greg Robertson is chief of the Emory Heart and Vascular Clinic at Johns Creek. At the Emory Johns Creek Hospital he is chief of cardiology and the medical director of the cardiac catheterization laboratory and interventional program. He is board certified in Vascular Medicine, Endovascular Medicine, Interventional Cardiology and Cardiovascular Medicine. He is an associate professor of medicine at Emory University. Dr. Robertson's clinical expertise has focused on preventative care and using minimally-invasive vascular and cardiac treatment.

SO NOW YOU'RE THINKING, WHY SHOULD I PAY ATTENTION TO THIS NEW TECHNOLOGY? BEING FACT DRIVEN, HISTORICALLY, THERE HAS BEEN SIGNIFICANT GROWTH IN WEARABLE TECHNOLOGY STOCKS.

The Next Chapter For Wearables Is Happening NOW

Alphabet (GOOGL) with a market cap of \$635.96 billion has a current share price of more than \$950. Verily is their new wearable a study watch that captures health data. According to the post, the watch represents efforts to create, "new tools for unobtrusive biosensing".

Apple (AAPL) with a market cap of 728.30 billion and current share price of over \$140 has the Apple Watch. The Series 1 launched in 2015 and was the world's best selling wearable that year with 4.2 million sold in the second quarter of 2015. Apple reported the "best quarter ever" in the wearable technology market.

Dexcom (DXCM) with a market cap of \$6.09 billion has a current share price over \$70. It has a medical device company and designed glucose monitoring (CGM) systems for those with diabetes and for healthcare providers. Dexcom now has its fifth generation CGM system, Dexcom G5 Mobile CGM system, which utilizes Bluetooth technology built into the transmitter.

With huge leaders in the industry continuing to grow and develop in the wearable medical device market why not take advantage when you can before it's too late.

As you can see, the industry has immense potential.

It isn't every day that you see companies like Apple and Alphabet investing billions of dollars into the space.

Instead of spending thousands of dollars for a few shares of stock from companies like these where it would take more than just a few dollars to see meaningful returns, **small cap stocks can present opportunity for exponential gains!**

Lexington Bioscience (LXGTF) has created a unique platform to take advantage of the industry growth in a niche that could be set to carve its own marketplace. Meanwhile, the timing of this could be very important for those looking for a near term opportunity.

According to **(LXGTF)** the Company has communicated with the FDA its strategic plan for a 510(K) submission. **(LXGTF)** has explained that interactions with the FDA to date have been positive and collaborative, providing increased confidence with our chosen regulatory and testing strategies. Typically speaking, this could mean that the launch of their product isn't too far off!

Early investors have capitalized off the growth that Apple and Alphabet demonstrated early on and now **Lexington Biosciences (LXGTF)** could be showing similar first mover potential.

Ready for More Info on **(LXGTF)**?

TechStockInsider.com is owned by Midam Ventures, LLC has been compensated \$100,000.00 by Ellis Stewart, LLC for a period beginning October 1, 2017 and ending November 1, 2017 & Midam Ventures, LLC has been compensated an additional \$150,000.00 by Ellis Stewart, LLC for a period beginning November 1, 2017 and ending December 1, 2017 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. [Click Here For Full Disclaimer](#).

Abraham Mason

<http://techstockinsider.com>